GLMD GLMD

Galmed Pharmaceuticals Stock Price

0.30
0.0081 (2.77%)
0.30
Volume 100
Bid Price 0.29
Ask Price 0.30
News -
Day High

Low
0.29

52 Week Range

High
2.6899

Day Low
Company Name Stock Ticker Symbol Market Type
Galmed Pharmaceuticals Ltd GLMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0081 2.77% 0.30 08:05:48
Open Price Low Price High Price Close Price Prev Close
0.2919
Trades Volume Avg Volume 52 Week Range
1 100 - 0.29 - 2.6899
Last Trade Time Type Quantity Stock Price Currency
08:05:48 formt 100 $ 0.30 USD

Period:

Draw Mode:

Galmed Pharmaceuticals Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.33M 21.11M 21.70M $ - $ - -1.32 -0.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Galmed Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GLMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.310.330.290.300508226,098-0.01-3.23%
1 Month0.390.410.290.330121233,108-0.09-23.08%
3 Months0.43490.490.290.375741437,699-0.1349-31.02%
6 Months0.51210.750.290.485145270,415-0.2121-41.42%
1 Year2.582.68990.291.1094,100-2.28-88.37%
3 Years4.687.380.293.32151,726-4.38-93.59%
5 Years8.0627.060.297.26165,321-7.76-96.28%

Galmed Pharmaceuticals Description

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.